Tolmar Pharmaceuticals

Welcome to the FENSOLVI^® MediaRoom

All multi-media content here is available for use…

Fensolvi is the only six-month, subcutaneously administered leuprolide acetate approved for the treatment of pediatric patients two years of age and older with Central Precocious Puberty Contact:  Julie Ferguson, Healthcare Communications Consultant JFPR Media, LLC Julie@jfprmedia.com (312) 385-0098

Open »